title: [The efficacy and safety of mismatched hematopoietic stem cell transplantation for treatment of severe aplastic anemia].
abstract: OBJECTIVE
  To study the efficacy and safety of human leukocyte antigen (HLA) mismatched hematopoietic stem cell transplantation (HSCT) on severe aplastic anemia (SAA).
  
  
  METHODS
  From January 2006 to May 2010, 17 patients received mismatched HSCT. HLA antigens were 3-loci-mismatched in 9 patients, 2-loci-mismatched in 8. All patients received recombinant human granulocyte colony-stimulating factor (rhG-CSF) primed bone marrow cells plus peripheral blood stem cells after modified busulfan/cyclophosphamide + antithymocyte immunoglobulin (BU/CY + ATG) conditioning regimen.
  
  
  RESULTS
  All patients achieved full donor type engraftment. Grade III-IV graft versus host disease (GVHD) occurred in 3 patients and extensive chronic GVHD in 1. With a median following-up time of 285 (60 - 1670) d, 11 patients were alive, 9 of them had normal blood counts and the other 2 were blood transfusion independent. Six patients died of transplant-related complications.
  
  
  CONCLUSIONS
  Mismatched HSCT is a feasible and safe option for SAA patients without sibling identical donors.
authors: Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
authors: Wei
authors: W
authors: Han
authors: Xiao-Jun
authors: XJ
authors: Huang
authors: Kai-Yan
authors: KY
authors: Liu
authors: Lan-Ping
authors: LP
authors: Xu
authors: Dai-Hong
authors: DH
authors: Liu
authors: Huan
authors: H
authors: Chen
authors: Xiao-Hui
authors: XH
authors: Zhang
authors: Yu-Hong
authors: YH
authors: Chen
authors: Feng-Rong
authors: FR
authors: Wang
authors: Yu
authors: Y
authors: Wang